US Pharma MarketingThe post Oragenics opens second site for ONP-002 Phase IIa trial appeared first on Clinical Trials Arena.
Oragenics opens second site for ONP-002 Phase IIa trial
Oragenics has activated a second site, Alfred Hospital, for its ongoing Phase IIa clinical trial of ONP-002, its lead treatment candidate for concussion and mTBI. Oragenics anticipates clinical data readout by year-end 2026 to support FDA application and US Phase IIb trials. ONP-002 has demonstrated safety and tolerability in Phase I clinical trials, with no serious adverse events reported at any dose. Credit: Gorodenkoff / Shutterstock.com. Oragenics has activated a second site for its ongoing Phase IIa clinical trial of ONP-002, its lead treatment candidate for concussion and mild traumatic brain injury (mTBI). The site, Alfred Hospital, is currently enrolling…
Oragenics has activated a second site, Alfred Hospital, for its ongoing Phase IIa clinical trial of ONP-002, its lead treatment candidate for concussion and mTBI.
Source: Clinical Trials Arena